-
Predicting overall survival and prophylactic cranial irradiation benefit in small-cell lung cancer with CT-based deep learning: A retrospective multicenter study Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-12 Xiaomin Zheng, Kaicai Liu, Na Shen, Yankun Gao, Chao Zhu, Cuiping Li, Chang Rong, Shuai Li, Baoxin Qian, Jianying Li, Xingwang Wu
To develop a computed tomography (CT)-based deep learning model to predict overall survival (OS) among small-cell lung cancer (SCLC) patients and identify patients who could benefit from prophylactic cranial irradiation (PCI) based on OS signature risk stratification. This study retrospectively included 556 SCLC patients from three medical centers. The training, internal validation, and external validation
-
A population-based analysis of the impact of 1 vs. 2 doses of mitomycin on patterns of failure of anal cancer patients treated with concurrent chemoradiotherapy Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-12 Kurian Joseph, Zainab Al Habsi, Aswin Abraham, Arun Elangovan, Sunita Ghosh, Truo-Mingh Pham, Devika Shreekumar, Zeyana Ramji, Kim Paulson, Keith Tankel, Nawaid Usmani, Diane Severin, Dan Schiller, Clarence Wong, Karen Mulder, Hatim Karachiwala, Corinne Doll, Karen King, Tirath Nijjar
We report the impact of 1 vs. 2 doses of mitomycin-C (MMC) based chemoradiation (CRT) on patterns of treatment failure and long-term patient outcomes in anal squamous cell carcinoma (ASCC) and the predictors for locoregional failure (LRF) and distant metastasis (DM). In this population-based study, we identified all patients with anal cancer in our province treated radically with radiation and concurrent
-
A systematic review of circulating predictive and prognostic biomarkers to aid the personalised use of radiotherapy in the radical treatment of patients with oesophageal cancer Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-11 Dylan McClurg, Chandan Sanghera, Somnath Mukherjee, Rebecca C. Fitzgerald, Christopher M. Jones
The availability of circulating biomarkers that are predictive of treatment response or prognostic of overall outcome could enable the personalised and adaptive use of radiotherapy (RT) in patients with oesophageal adenocarcinoma (OAC) and squamous cell carcinoma (OSCC). A systematic review was carried out following Preferred Reporting Items for Systematic Reviews guidance. Medline, EMBASE, PubMed
-
Dosimetric impact of bone marrow sparing for robustly optimized IMPT for locally advanced cervical cancer Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-11 S.C. Kuipers, J. Godart, A. Corbeau, S. Breedveld, J.W.M. Mens, S.M. de Boer, R.A. Nout, M.S. Hoogeman
To investigate the trade-off between bone marrow sparing (BMS) and dose to organs at risk (OARs) for intensity modulated proton therapy (IMPT) for women with locally advanced cervical cancer (LACC). Twenty LACC patients were retrospectively included. IMPT plans were created for each patient using automated treatment planning. These plans progressively reduced bone marrow mean doses by steps of 1 GyRBE
-
Longitudinal changes in the carotid arteries of head and neck cancer patients following radiation therapy: Results from a prospective serial imaging biomarker characterization study Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-11 Efstratios Koutroumpakis, Abdallah Sherif Radwan Mohamed, Peter Chaftari, David I. Rosenthal, Dorothy Gujral, Christopher Nutting, Serageldin Kamel, Mohamed A. Naser, Peter Kim, Roland Bassett, Clifton D. Fuller, Elie Mouhayar, MD Anderson Head Neck Radiation Oncology Cardiovascular Working Group
We prospectively evaluated morphologic and functional changes in the carotid arteries of patients treated with unilateral neck radiation therapy (RT) for head and neck cancer. Bilateral carotid artery duplex studies were performed at 0, 3, 6, 12, 18 months and 2, 3, 4, and 5 years following RT. Intima media thickness (IMT); global and regional circumferential, as well as radial strain, arterial elasticity
-
Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-11 Feng Liu, Doris R. Brown, Michael T. Munley
Stereotactic body radiation therapy (SBRT) has been emerging as an efficacious and safe treatment modality for early-stage hepatocellular carcinoma (HCC), but optimal fractionation regimens are unknown. This study aims to analyze published clinical tumor control probability (TCP) data as a function of biologically effective dose (BED) and to determine radiobiological parameters and optimal fractionation
-
Dose-response of localized renal cell carcinoma after stereotactic body radiation therapy: A meta-analysis Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-09 Ryan S. Huang, Ronald Chow, Pradnya Chopade, Andrew Mihalache, Asad Hasan, Gabriel Boldt, Rachel Glicksman, Charles B. Simone, Michael Lock, Srinivas Raman
Stereotactic ablative radiation therapy (SBRT) is an emerging treatment option for primary renal cell carcinoma (RCC), particularly in patients who are unsuitable for surgery. The aim of this review is to assess the effect of increasing the biologically equivalent dose (BED) via various radiation fractionation regimens on clinical outcomes. A literature search was conducted in PubMed (Medline), EMBASE
-
Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-08 Jean-Michel Hannoun-Levi, Marta Gimeno Morales, Jocelyn Gal, Javier Anchuelo, Jose-Luis Guinot, Miren Gastanaga, Norbert Meszaros, Csaba Polgar, Vratislav Strnad, Renaud Schiappa, Cristina Gutierrez
To analyze late toxicity after very accelerated partial breast irradiation (VAPBI) for low-risk breast cancer. Methods In this retrospective, observational, international multicenter study (HDH F20220713143949), patients with low-risk breast cancer underwent lumpectomy + vAPBI (high-dose rate multicatheter interstitial brachytherapy-MIBT). VAPBI was performed with 4(4x6.2 Gy/2d), 3(3x7.45 Gy/2d) or
-
European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-07 Sophia Scharl, Constantinos Zamboglou, Iosif Strouthos, Andrea Farolfi, Francesca Serani, Stefan A. Koerber, Jürgen Debus, Jan C. Peeken, Marco M.E. Vogel, Stephanie G.C. Kroeze, Matthias Guckenberger, Manuel Krafcsik, George Hruby, Louise Emmett, Nina-Sophie Schmidt-Hegemann, Christian Trapp, Simon K.B. Spohn, Christoph Henkenberens, Benjamin Mayer, Mohamed Shelan, Daniel M. Aebersold, Reinhard Thamm
The European Association of Urology (EAU) proposed a risk stratification (high vs. low risk) for patients with biochemical recurrence (BR) following radical prostatectomy (RP). Here we investigated whether this stratification accurately predicts outcome, particularly in patients staged with PSMA-PET. For this study, we used a retrospective database including 1222 PSMA-PET-staged prostate cancer patients
-
Baseline shift corrections towards the heart: External validation of the impact on survival in early-stage NSCLC patients Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-07 Celia Juan-Cruz, Barbara Stam, Maddalena Rossi, Jose Belderbos, Jan-Jakob Sonke
To externally validate Johnson-Hart et al. findings: the association of tumor baseline shifts towards the heart with overall survival(OS) in SBRT for NSCLC. Further analysis included investigating the presence of interfractional heart baseline shifts and the association of OS with heart dose change during treatment. Data from 416 SBRT early-stage NSCLC patients was collected. Pearson’s correlations(PCCs)
-
Low-dose radiotherapy synergizes with iRGD-antiCD3-modified T cells by facilitating T cell infiltration Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-07 Shujuan Zhou, Mei Zhu, Xiao Wei, Peiyuan Mu, Lijun Shen, Yan Wang, Juefeng Wan, Hui Zhang, Fan Xia, Zhen Zhang
Poor penetration of transferred T cells represents a critical factor impeding the development of adoptive cell therapy in solid tumors. We demonstrated that iRGD-antiCD3 modification promoted both T cell infiltration and activation in our previous work. Interest in low-dose radiotherapy has recently been renewed due to its immuno-stimulatory effects including T cell recruitment. This study aims to
-
Proton therapy induces a local microglial neuroimmune response Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-06 Daniëlle C. Voshart, Myrthe Klaver, Yuting Jiang, Hilmar R.J. van Weering, Fleur van Buuren-Broek, Gideon P. van der Linden, Davide Cinat, Harry H. Kiewiet, Justin Malimban, Daniel A. Vazquez-Matias, Luiza Reali Nazario, Ayla C. Scholma, Jeffrey Sewdihal, Marc-Jan van Goethem, Peter van Luijk, Rob P. Coppes, Lara Barazzuol
[Display omitted]
-
Dose and dose rate dependence of the tissue sparing effect at ultra-high dose rate studied for proton and electron beams using the zebrafish embryo model Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-05 Felix Horst, Elisabeth Bodenstein, Michael Brand, Stefan Hans, Leonhard Karsch, Elisabeth Lessmann, Steffen Löck, Michael Schürer, Jörg Pawelke, Elke Beyreuther
A better characterization of the dependence of the tissue sparing effect at ultra-high dose rate (UHDR) on physical beam parameters (dose, dose rate, radiation quality) would be helpful towards a mechanistic understanding of the FLASH effect and for its broader clinical translation. To address this, a comprehensive study on the normal tissue sparing at UHDR using the zebrafish embryo (ZFE) model was
-
Multi-centre evaluation of variation in cumulative dose assessment in reirradiation scenarios Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-05 Nicholas Hardcastle, Eliana Vasquez Osorio, Andrew Jackson, Charles Mayo, Anja Einebærholm Aarberg, Myriam Ayadi, Francesca Belosi, Cemile Ceylan, Angela Davey, Pauline Dupuis, Julia-Claire Handley, Theresa Hemminger, Lone Hoffmann, Colin Kelly, Chrysanthi Michailidou, Sarah Muscat, Donna H. Murrell, Jaime Pérez-Alija, Catherine Palmer, Lorenzo Placidi, Marija Popovic, Heidi S. Rønde, Adam Selby, Theodora
[Display omitted]
-
Targeting the CXCL12/CXCR4 pathway to reduce radiation treatment side effects Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-05 Naz Chaudary, Richard P. Hill, Michael Milosevic
High precision, image-guided radiotherapy (RT) has increased the therapeutic ratio, enabling higher tumor and lower normal tissue doses, leading to improved patient outcomes. Nevertheless, some patients remain at risk of developing serious side effects.In many clinical situations, the radiation tolerance of normal tissues close to the target volume limits the dose that can safely be delivered and thus
-
Benefit of respiratory gating in the Danish Breast Cancer Group partial breast irradiation trial Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-03 Kristine W. Høgsbjerg, Else Maae, Mette H. Nielsen, Lars Stenbygaard, Anders N. Pedersen, Esben Yates, Martin Berg, Ebbe L. Lorenzen, Ingelise Jensen, Mirjana Josipovic, Mette S. Thomsen, Birgitte V. Offersen
Partial breast irradiation (PBI)has beenthe Danish Breast Cancer Group(DBCG) standard for selected breast cancer patients since 2016 based onearlyresults from the DBCG PBI trial.During trial accrual, respiratory-gated radiotherapy was introduced in Denmark. This study aims to investigate the effect of respiratory-gating on mean heart dose (MHD). From 2009 to 2016 the DBCG PBI trial included 230 patientswith
-
Neurological complications of modern radiotherapy for head and neck cancer Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-02 James C.H. Chow, Jason C.S. Ho, Ka Man Cheung, David Johnson, Bonaventure Y.M. Ip, Jonathan J. Beitler, Primož Strojan, Antti A. Mäkitie, Avraham Eisbruch, Sweet Ping Ng, Sandra Nuyts, William M. Mendenhall, Silvia Babighian, Alfio Ferlito
Radiotherapy is one of the mainstay treatment modalities for the management of non-metastatic head and neck cancer (HNC). Notable improvements in treatment outcomes have been observed in the recent decades. Modern radiotherapy techniques, such as intensity-modulated radiotherapy and charged particle therapy, have significantly improved tumor target conformity and enabled better preservation of normal
-
Four steps in the evolution of rectal cancer managements through 40 years of clinical practice: Pioneering, standardization, challenges and personalization Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-02 Vincenzo Valentini, Sergio Alfieri, Claudio Coco, Domenico D'Ugo, Antonio Crucitti, Fabio Pacelli, Roberto Persiani, Luigi Sofo, Aurelio Picciocchi, Giovanni Battista Doglietto, Brunella Barbaro, Fabio Maria Vecchio, Riccardo Ricci, Andrea Damiani, Maria Chiara Savino, Luca Boldrini, Francesco Cellini, Elisa Meldolesi, Angela Romano, Giuditta Chiloiro, Maria Antonietta Gambacorta
-
Long-term results of intraoperative multicatheter breast implant (IOMBI) for accelerated partial breast irradiation (APBI) on early breast cancer patients Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-02 Marta Gimeno-Morales, Rafael Martínez-Monge, Adriana Martinez-Lage, Paola Anna Jablonska, Javier Blanco, Fernando Martínez-Regueira, Natalia Rodriguez-Spiteri, Begoña Olartecoechea, Luis Ramos, Luis Pina Insausti, Arlette Elizalde, Marta Abengozar, Mauricio Cambeiro
Multicatheter breast brachytherapy is a standard technique for accelerated partial breast irradiation (APBI) in early breast cancer patients. Intraoperative multicatheter breast implant (IOMBI) followed by perioperative high-dose-rate brachytherapy (PHDRBT) offers a novel and advantageous approach. We present long-term oncological, toxicity, and cosmesis outcomes for a well-experienced single institution
-
Less than whole uterus irradiation for patients with locally advanced cervical cancer Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-02 Caressa Hui, Agnes Ewongwo, Maria G. Mendoza, Margaret M. Kozak, Scott Jackson, Jie Fu, Elizabeth Kidd
Current consensus guidelines for definitive cervical cancer intensity modulated radiation therapy (IMRT) recommend inclusion of the entire uterus within the clinical target volume, however this is debated. We aimed to evaluate outcomes of patients with cervical cancer who were treated with less than whole uterus irradiation. We identified 109 patients with FIGO Stage IB-IVA cervical cancer treated
-
Characterization of the signal transduction cascade for inflammatory gene expression in fibroblasts with ATM-ATR deficiencies after Ionizing radiation Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-02 Shunji Haruna, Ken Okuda, Akiko Shibata, Mayu Isono, Kohei Tateno, Hiro Sato, Takahiro Oike, Yuki Uchihara, Yu Kato, Atsushi Shibata
Ionizing radiation (IR) induces DNA double-strand breaks (DSBs), leading to micronuclei formation, which has emerged as a key mediator of inflammatory responses after IR. This study aimed to investigate the signaling cascade in inflammatory gene expression using fibroblasts harboring DNA damage response deficiency after exposure to IR. Micronuclei formation was examined in human dermal fibroblasts
-
Assessment of bias in scoring of AI-based radiotherapy segmentation and planning studies using modified TRIPOD and PROBAST guidelines as an example Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-02 Coen Hurkmans, Jean-Emmanuel Bibault, Enrico Clementel, Jennifer Dhont, Wouter van Elmpt, Georgios Kantidakis, Nicolaus Andratschke
Studies investigating the application of Artificial Intelligence (AI) in the field of radiotherapy exhibit substantial variations in terms of quality. The goal of this study was to assess the amount of transparency and bias in scoring articles with a specific focus on AI based segmentation and treatment planning, using modified PROBAST and TRIPOD checklists, in order to provide recommendations for
-
Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study Radiother. Oncol. (IF 5.7) Pub Date : 2024-03-01 Wei-Wei Zhang, Jia-Yi Lin, Gao-Yuan Wang, Cheng-Long Huang, Ling-Long Tang, Yan-Ping Mao, Guan-Qun Zhou, Li-Zhi Liu, Li Tian, Ji-Bin Li, Jun Ma, Rui Guo
Whether concurrent chemoradiotherapy would provide survival benefits in patients with stage II and T3N0 NPC with adverse factors remains unclear in IMRT era. We aimed to assess the value of concurrent chemotherapy compared to IMRT alone in stage II and T3N0 NPC with adverse features. 287 patients with stage II and T3N0 NPC with adverse factors were retrospectively analyzed, including 98 patients who
-
Impact of electronic patient-reported outcome measures on patients’ perception of the physician - the randomized ePREFERENCE study Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-29 C. Gani, P. Bickenbach, A. Tenev, M. Niyazi, T. Festl-Wietek, A. Herrmann-Werner
Electronic Patient-reported outcome measures (ePROMs) are increasingly used in radiotherapy departments. However, the impact of ePROM integration on patients’ perceptions of healthcare providers, particularly in terms of empathy and professionalism, remains unclear. Thus, this study aims to assess the patients’ views on healthcare professionals during ePROM-based consultations. In this randomized trial
-
Letter to the editor regarding “External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts” by M. Berbée et al. Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-28 P. Populaire, G. Defraene, K. Haustermans
-
Skin dose-volume predictors of moderate-severe late side effects after whole breast radiotherapy Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-27 Alessandro Cicchetti, Paola Mangili, Andrei Fodor, Maria Giulia Ubeira Gabellini, Anna Chiara, Chiara Deantoni, Martina Mori, Marcella Pasetti, Gabriele Palazzo, Tiziana Rancati, Antonella del Vecchio, Nadia Gisella Di Muzio, Claudio Fiorino
Toxicity after whole breast Radiotherapy is a relevant issue, impacting the quality-of-life of a not negligible number of patients. We aimed to develop a Normal Tissue Complication Probability (NTCP) model predicting late toxicities by combining dosimetric parameters of the breast dermis and clinical factors. The skin structure was defined as the outer CT body contour's 5 mm inner isotropic expansion
-
The role of 18F-FDG PET in minimizing variability in gross tumor volume delineation of soft tissue sarcomas Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-25 Elie Najem, Thibault Marin, Yue Zhuo, Rita Maria Lahoud, Fei Tian, Arnaud Beddok, Laura Rozenblum, Fangxu Xing, Maryam Moteabbed, Ruth Lim, Xiaofeng Liu, Jonghye Woo, Stephen John Lostetter, Abdallah Lamane, Yen-Lin Evelyn Chen, Chao Ma, Georges El Fakhri
Accurate gross tumor volume (GTV) delineation is a critical step in radiation therapy treatment planning. However, it is reader dependent and thus susceptible to intra- and inter-reader variability. GTV delineation of soft tissue sarcoma (STS) often relies on CT and MR images. This study investigates the potential role of F-FDG PET in reducing intra- and inter-reader variability thereby improving reproducibility
-
Partially Ablative Body Radiotherapy (PABR): A novel approach for palliative radiotherapy of locally advanced bulky unresectable sarcomas Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-25 Kelvin Ken Yu, Adam Yeo, Samuel Ngan, Julie Chu, David Chang, Shankar Siva, Aaron Wong, Tomas Kron, Nicholas Hardcastle, Mathieu Gaudreault, Therese Chesson, Siena Williams, Mark Burns, Sarat Chander
Locally advanced, bulky, unresectable sarcomas cause significant tumour mass effects, leading to burdensome symptoms. We have developed a novel Partially Ablative Body Radiotherapy (PABR) technique that delivers a high, ablative dose to the tumour core and a low, palliative dose to its periphery aiming to increase overall tumour response without significantly increasing treatment toxicity. This study
-
ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I/II trial Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-24 Thomas Zilli, Ciro Franzese, Matthias Guckenberger, Niccolò Giaj-levra, Nicolas Mach, Nikolaos Koutsouvelis, Verane Achard, Andrew Mcdonald, Filippo Alongi, Marta Scorsetti, Guillaume Constantin, Aurelie Bertaut, Raymond Miralbell
To assess in a prospective, multicenter, single-arm phase I/II study the early safety and efficacy profile of single fraction urethra-sparing stereotactic body radiotherapy (SBRT) for men with localized prostate cancer. Patients with low- and intermediate-risk localized prostate cancer without significant tumor in the transitional zone were recruited. A single-fraction of 19 Gy was delivered to the
-
Improved delineation with diffusion weighted imaging for laryngeal and hypopharyngeal tumors validated with pathology Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-24 Hilde J.G. Smits, Cornelis P.J. Raaijmakers, Mischa de Ridder, Zeno A.R. Gouw, Patricia A.H. Doornaert, Frank A. Pameijer, Joyce E. Lodeweges, Lilian N. Ruiter, Koen M. Kuijer, Tim Schakel, Remco de Bree, Jan W. Dankbaar, Chris H.J. Terhaard, Gerben E. Breimer, Stefan M. Willems, Marielle E.P. Philippens
This study aims to determine the added value of a geometrically accurate diffusion-weighted (DW-) MRI sequence on the accuracy of gross tumor volume (GTV) delineations, using pathological tumor delineations as a ground truth. Sixteen patients with laryngeal or hypopharyngeal carcinoma were included. After total laryngectomy, the specimen was cut into slices. Photographs of these slices were stacked
-
Dose-averaged LET optimized carbon-ion radiotherapy for head and neck cancers Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-24 Masashi Koto, Hiroaki Ikawa, Taku Inaniwa, Reiko Imai, Makoto Shinoto, Hirotoshi Takiyama, Tetsuro Isozaki, Hideyuki Mizuno, Ryosuke Kohno, Ikumi Takahashi, Naoki Yoshida, Shigeru Yamada
This feasibility study confirmed the initial safety and efficacy of a novel carbon-ion radiotherapy (CIRT) using linear energy transfer (LET) painting for head and neck cancer. This study is the first step toward establishing CIRT with LET painting in clinical practice and making it a standard practice in the future.
-
Deep match: A zero-shot framework for improved fiducial-free respiratory motion tracking Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-24 Di Xu, Martina Descovich, Hengjie Liu, Yi Lao, Alexander R. Gottschalk, Ke Sheng
Motion management is essential to reduce normal tissue exposure and maintain adequate tumor dose in lung stereotactic body radiation therapy (SBRT). Lung SBRT using an articulated robotic arm allows dynamic tracking during radiation dose delivery. Two stereoscopic X-ray tracking modes are available – fiducial-based and fiducial-free tracking. Although X-ray detection of implanted fiducials is robust
-
Response to letter to the editor regarding “External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts” by M. Berbée et al. Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-18 M. Berbée, C.T. Muijs, E. Schuit
-
Very high-energy electron therapy as light-particle alternative to transmission proton FLASH therapy – An evaluation of dosimetric performances Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-18 Till Tobias Böhlen, Jean‐François Germond, Laurent Desorgher, Izabella Veres, Andreas Bratel, Eric Landström, Erik Engwall, Fernanda G. Herrera, Esat Mahmut Ozsahin, Jean Bourhis, François Bochud, Raphaël Moeckli
Clinical translation of FLASH-radiotherapy (RT) to deep-seated tumours is still a technological challenge. One solution consists of using ultra-high dose rate transmission proton (TP) beams of about 200-250MeV to irradiate the tumour with the flat entrance of the proton depth-dose profile. This work evaluates the dosimetric performance of very high-energy electron (VHEE)-based RT (50-250MeV) as a potential
-
Early regression index (ERI) on MR images as response predictor in esophageal cancer treated with neoadjuvant chemo-radiotherapy: Interim analysis of the prospective ESCAPE trial Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-16 C. Fiorino, D. Palumbo, M. Mori, G. Palazzo, A.E. Pellegrini, L. Albarello, A. Belardo, C. Canevari, A. Cossu, A. Damascelli, U. Elmore, E. Mazza, M. Pavarini, P. Passoni, F. Puccetti, N. Slim, S. Steidler, A. Del Vecchio, N.G. Di Muzio, A. Chiti, R. Rosati, F. De Cobelli
The early regression index (ERI) predicts treatment response in rectal cancer patients. Aim of current study was to prospectively assess tumor response to neoadjuvant chemo-radiotherapy (nCRT) of locally advanced esophageal cancer using ERI, based on MRI. From January 2020 to May 2023, 30 patients with esophageal cancer were enrolled in a prospective study (ESCAPE). PET-MRI was performed: i) before
-
-
Brainstem toxicity after proton or photon therapy in children and young adults with localized intracranial ependymoma: A French retrospective study Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-16 Céline Dalmasso, Claire Alapetite, Stéphanie Bolle, Farid Goudjil, Amélie Lusque, Jacques Desrousseaux, Line Claude, Jérome Doyen, Valérie Bernier-Chastagner, Anne Ducassou, Annick Sevely, Margaux Roques, Fatima Tensaouti, Anne Laprie
Ependymoma is the third most frequent childhood braintumor. Standard treatment is surgery followed by radiation therapy including proton therapy (PBT). Retrospective studies have reported higher rates of brainstem injury after PBT than after photon therapy (XRT). We report a national multicenter study of the incidence of brainstem injury after XRT versus PBT, and their correlations with dosimetric
-
Aims+Scope/Editorial Board/ Publication information Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-16
-
The Management of Stage I Non-Small Cell Lung Cancer (NSCLC) in Ontario: A Population-Based Study of Patterns of Care and Stereotactic Ablative Body Radiotherapy (SABR) Utilization from 2010-2019 Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-15 Allison Ashworth, Weidong Kong, Timothy Owen, Timothy P. Hanna, Michael Brundage
-
The individualized delineation of clinical target volume for primary nasopharyngeal carcinoma based on invasion risk of substructures: A prospective, real-word study with a large population Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-15 Xiaohui Wang, Nan Huang, Pui Lam Yip, Jing Wang, Runda Huang, Zhuang Sun, Dehua Kang, Qian He, Xiaowu Deng, Chong Zhao, Melvin L.K. Chua, Fei Han
The delineation of clinical target volume (CTV) for primary nasopharyngeal carcinoma (NPC) is currently controversial and the international guideline still recommend a uniform border for CTV regardless of the tumor extent. We conducted this prospective, real-world study to evaluate the clinical outcomes of our individualized CTV delineation method based on distance plus substructures. We preliminarily
-
Correspondence: Comprehensive insights on the underlying potential and advantage of proton therapy over intensity-modulated photon radiation therapy as highlighted in a wide real world data analysis Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-12 Chia-Lun Chang, Kuan-Chou Lin, Wan-Ming Chen, Ben-Chang Shia, Szu-Yuan Wu
-
Response letter to “Stereotactic body radiation therapy for pleural mesothelioma: Which goal, which patients” Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-10 Jacob Y. Shin, Michael Offin, Charles B. Simone II, Annemarie F. Shepherd, Abraham J. Wu, Narek Shaverdian, Daphna Y. Gelblum, Daniel R. Gomez, Jennifer L. Sauter, Michelle S. Ginsberg, Prasad S. Adusumilli, Valerie W. Rusch, Marjorie G. Zauderer, Andreas Rimner
-
Stereotactic body radiation therapy for pleural mesothelioma: Which goal, which patients: Comment to “Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma” by Shin et al. Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-09 Giovanni L. Ceresoli, Paolo Ghirardelli, Vittorio Vavassori
-
Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-09 I. Smesseim, O.M. Mets, J.M.A. Daniels, I. Bahce, S. Senan
In inoperable stage III NSCLC, the standard of care is chemoradiotherapy and adjuvant durvalumab (IO) for 12 months. Pneumonitis is the commonest toxicity leading to discontinuation of IO. A failure to distinguish between expected radiation-induced changes, IO pneumonitis and infection can lead to unnecessary durvalumab discontinuation. We investigated the use of a structured multidisciplinary review
-
Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma – A DAHANCA 19 study Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-09 Morten Horsholt Kristensen, Mia Kristina Sørensen, Trine Tramm, Jan Alsner, Brita Singers Sørensen, Christian Maare, Jørgen Johansen, Hanne Primdahl, Åse Bratland, Claus Andrup Kristensen, Maria Andersen, Jacob Kinggaard Lilja-Fischer, Anne Ivalu Sander Holm, Eva Samsøe, Christian Rønn Hansen, Ruta Zukauskaite, Jens Overgaard, Jesper Grau Eriksen
Reliable and accessible biomarkers for patients with Head and Neck Squamous Cell Carcinoma (HNSCC) are warranted for biologically driven radiotherapy (RT). This study aimed to investigate the prognostic value of putative cancer stem cell (CSC) markers, hypoxia, and tumor volume using loco-regional high-dose failure (HDF) as endpoint. Tumor tissue was retrieved from patients treated with primary chemo-(C-)RT
-
Optimal timing of re-planning for head and neck adaptive radiotherapy Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-08 Yong Gan, Johannes A. Langendijk, Edwin Oldehinkel, Zhixiong Lin, Stefan Both, Charlotte L. Brouwer
Adaptive radiotherapy (ART) relies on re-planning to correct treatment variations, but the optimal timing of re-planning to account for dose changes in head and neck organs at risk (OARs) is still under investigation. We aimed to find out the optimal timing of re-planning in head and neck ART. A total of 110 head and neck cancer patients were retrospectively enrolled. A semi auto-segmentation method
-
Applying the fragility index to randomized controlled trials evaluating total neoadjuvant therapy for rectal cancer: A methodological survey Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-08 Tyler McKechnie, Kelly Brennan, Cagla Eskicioglu, Ameer Farooq, Sunil V Patel
Recently, there has been significant interest in, and adoption of, total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC). We designed the present study to assess the robustness of the randomized controlled trials (RCTs) evaluating contemporary TNTs for LARC using the fragility index (FI). Relevant articles were identified through a review article by Johnson in the . Dichotomous
-
Multi-domain neurocognitive impairment following definitive intensity-modulated radiotherapy for nasopharyngeal cancer: A cross-sectional study Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-08 James C.H. Chow, Jack Lee, Maria M.P. Lai, Sara Li, Adelina M.C. Lau, Beni S.Y. Ng, Gigi G.G. Leung, Sharon T.Y. Li, Jeffrey C.F. Lui, Ka Man Cheung, Kwok Hung Au, Kam Hung Wong, Alexander Y.L. Lau, Benny C.Y Zee
Neurocognitive impairment from inadvertent brain irradiation is common following intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma (NPC). This study aimed to determine the prevalence, pattern, and radiation dose-toxicity relationship of this late complication. We undertook a cross-sectional study of 190 post-IMRT NPC survivors. Neurocognitive function was screened using the Montreal
-
Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessment Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-08 Eric François, Nicolas Magné, Rabia Boulahssass, Philippe Ronchin, Virginie Huguenet, Blandine De Lavigerie, Elodie Nouhaud, Catherine Cattenoz, Isabelle Martel-Lafay, Catherine Terret, Pascal Artru, Pierre Clavere, Achille Tchalla, Véronique Vendrely, Sophie Duc, Valérie Boige, Nicolas De Sousa Carvalho, Jocelyn Gal, Berardino De Bari
The results of the PRODIGE 42/GERICO 12 study showed that short course radiotherapy had a better tolerance profile than radiochemotherapy, with comparable oncological results. We have included Quality of Life analyses and oncogeriatric evaluations in this study. In all, 101 patients ≥75 years of age with resectable T3-T4 rectal adenocarcinoma less than 12 cm from the anal margin received short course
-
Definitive single fraction spine stereotactic radiosurgery for metastatic sarcoma: Simultaneous integrated boost is associated with high tumor control and low vertebral fracture risk Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-03 Mihir D. Shanker, Adriana P. Cavazos, Jing Li, Thomas H. Beckham, Debra N. Yeboa, Chenyang Wang, Mary Frances McAleer, Tina Marie Briere, Behrang Amini, Claudio E. Tatsui, Robert Y. North, Christopher A. Alvarez-Breckenridge, Phillip Cem Cezayirli, Laurence D. Rhines, Amol J. Ghia, Andrew J. Bishop
Sarcoma spinal metastases (SSM) are particularly difficult to manage given their poor response rates to chemotherapy and inherent radioresistance. We evaluated outcomes in a cohort of patients with SSM uniformly treated using single-fraction simultaneous-integrated-boost (SIB) spine stereotactic radiosurgery (SSRS). A retrospective review was conducted at a single tertiary institution treated with
-
Common Sense (Radiation) Oncology: Redefining targets in radiotherapy Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-03 Nina N. Sanford, Yolande Lievens, Ajay Aggarwal, Timothy P. Hanna, Laura A. Dawson, Jeffrey White, Bishal Gyawali, Christopher Booth, Fabio Ynoe de Moraes
In 2023, the Common Sense Oncology (CSO) movement was launched with the goal of recalibrating cancer care to focus on outcomes that matter to patients. We extend the three CSO pillars – evidence generation, interpretation and communication – to radiation oncology and advocate for better evidence demonstrating the value of our modality.
-
Paediatric radiation therapy without anaesthesia – Are the children moving? Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-03 Tatiana Ritchie, Susan Awrey, Manjula Maganti, Rehab Chahin, Michael Velec, David C. Hodgson, Hitesh Dama, Sameera Ahmed, Jeff D. Winter, Normand Laperriere, Derek S. Tsang
Children who require radiation therapy (RT) should ideally be treated awake, without anaesthesia, if possible. Audiovisual distraction is a known method to facilitate awake treatment, but its effectiveness at keeping children from moving during treatment is not known. The aim of this study was to evaluate intrafraction movement of children receiving RT while awake. In this prospective study, we measured
-
Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-03 Lionel Perrier, Frédéric Balusson, Magali Morelle, Joël Castelli, Juliette Thariat, Karen Benezery, Ali Hasbini, Bernard Gery, Antoine Berger, Xavier Liem, Sébastien Guihard, Sophie Chapet, Sébastien Thureau, Pierre Auberdiac, Pascal Pommier, Amandine Ruffier, Anne Devillers, Emmanuel Oger, Boris Campillo-Gimenez, Renaud de Crevoisier
We performed a cost-effectiveness analysis (CEA) comparing an adaptive radiotherapy (ART) strategy, based on weekly replanning, aiming to correct the parotid gland overdose during treatment and expecting therefore to decrease xerostomia, when compared to a standard IMRT. We conducted the ARTIX trial, a randomized, parallel-group, multicentric study comparing a systematic weekly replanning ART to a
-
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-03 Kelsey L. Corrigan, Ting Xu, Yuki Sasaki, Ruitao Lin, Aileen B. Chen, James W. Welsh, Steven H. Lin, Joe Y. Chang, Matthew S. Ning, Saumil Gandhi, Michael S. O'Reilly, Carl M. Gay, Mehmet Altan, Charles Lu, Tina Cascone, Efstratios Koutroumpakis, Ajay Sheshadri, Xiaodong Zhang, Li Liao, X. Ronald Zhu, John V. Heymach, Quynh-Nhu Nguyen, Zhongxing Liao
Adjuvant immunotherapy (IO) following concurrent chemotherapy and photon radiation therapy confers an overall survival (OS) benefit for patients with inoperable locally advanced non-small cell lung carcinoma (LA-NSCLC); however, outcomes of adjuvant IO after concurrent chemotherapy with proton beam therapy (CPBT) are unknown. We investigated OS and toxicity after CPBT with adjuvant IO versus CPBT alone
-
Shared decision making with breast cancer patients – does it work? Results of the cluster-randomized, multicenter DBCG RT SDM trial Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-03 Stine Rauff Søndergaard, Troels Bechmann, Else Maae, Anders W. Mølby Nielsen, Mette Holck Nielsen, Mette Møller, Signe Timm, Ebbe Laugaard Lorenzen, Leonard L. Berry, Robert Zachariae, Birgitte Vrou Offersen, Karina Dahl Steffensen
Shared decision making (SDM) is a patient engaging process advocated especially for preference-sensitive decisions, such as adjuvant treatment after breast cancer. An increasing call for patient engagement in decision making highlights the need for a systematic SDM approach. The objective of this trial was to investigate whether the Decision Helper (DH), an in-consultation patient decision aid, increases
-
Application of postoperative adjuvant radiotherapy in limited-stage small cell lung cancer: A systematic review and meta-analysis Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-02 Chuanhao Zhang, Genghao Zhao, Huajian Wu, Jianing Jiang, Wenyue Duan, Zhijun Fan, Zhe Wang, Ruoyu Wang
One of the most important treatments for small cell lung cancer (SCLC) is radiation therapy. Currently, the criteria for administering postoperative adjuvant radiotherapy (PORT) in SCLC remain uncertain. Therefore, we conducted a meta-analysis to investigate the influence of PORT on the prognosis of limited-stage SCLC (LS-SCLC). We conducted a comprehensive search across three databases, PubMed, Embase
-
GEC-ESTRO survey of 106Ru eye applicator practice for ocular melanoma – Physicist survey Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-02 Marisol De Brabandere, Elisa Placidi, Frank-André Siebert, Åsa Carlsson Tedgren, Andrea Slocker Escarpa, Luca Tagliaferri, Michael Andrássy, Carmen Schulz, Lotte S. Fog
Ru eye plaque brachytherapy (BT, interventional radiotherapy) is an eye-preserving treatment for uveal melanoma performed in about 100 clinics worldwide. Despite this relatively low number, there is a considerable variation in clinical practice. In 2022, the BRAPHYQS and Head & Neck and Skin GEC-ESTRO working groups conducted a survey to map the current clinical practice. The survey consisted of a
-
Magnetic resonance imaging for assessment of rectal cancer nodes after chemoradiotherapy: A single center experience Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-02 Brunella Barbaro, Maria Rachele PIa Carafa, Laura Maria Minordi, Priscilla Testa, Giulia Tatulli, Davide Carano, Claudio Fiorillo, Giuditta Chiloiro, Angela Romano, Vincenzo Valentini, Maria Antonietta Gambacorta
Accurate nodal restaging is becoming clinically more important in patients with locally advanced rectal cancer (LARC) with the emergence of organ-preserving treatment after a good response to neoadjuvant chemoradiotherapy (nCRT). To evaluate the accuracy of MRI in identifying negative N status (ypN0 patients) in LARC after nCRT. 191 patients with LARC underwent MRI before and 6–8 weeks after nCRT and
-
Comprehensive insights on the underlying potential and advantage of proton therapy over intensity-modulated photon radiation therapy as highlighted in a wide real world data analysis Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-01 Ester Orlandi, Giulia Fontana, Lisa Licitra, Carmine Tinelli, Anna Maria Camarda, Cai Grau, Steven Jay Frank
Abstract not available
-
Disease and toxicity outcomes for a modern cohort of patients with squamous cell carcinoma of cutaneous origin involving the parotid gland: Comparison of volumetric modulated arc therapy and pencil beam scanning proton therapy Radiother. Oncol. (IF 5.7) Pub Date : 2024-02-01 Reza Zarinshenas, Peter Campbell, Kai Sun, Jason K. Molitoris, Akshar N. Patel, Matthew E. Witek, Kevin J. Cullen, Ranee Mehra, Kyle M. Hatten, Kelly F. Moyer, Rodney J. Taylor, Kalpesh T. Vakharia, Jeffrey S. Wolf, Matthew J. Ferris
We sought to describe outcomes for locally advanced cutaneous squamous cell carcinoma (SCC) involving the parotid treated with volumetric modulated arc therapy (VMAT) versus pencil beam scanning proton beam therapy (PBT). Patients were gathered from 2016 to 2022 from 5 sites of a large academic RT department; included patients were treated with RT and had parotid involvement by: direct extension of